Clinical Trial: Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation
Brief Summary: To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive diseases following hematopoietic stem cell transplantation.
Detailed Summary:
Sponsor: Seoul National University Hospital
Current Primary Outcome: AT-III level before 5th dose of AT-III [ Time Frame: up to 14 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome: AT-III level before 9th dose [ Time Frame: up to 14 days ]
Original Secondary Outcome: Same as current
Information By: Seoul National University Hospital
Dates:
Date Received: May 30, 2013
Date Started: June 2013
Date Completion: December 2018
Last Updated: April 26, 2017
Last Verified: December 2016